Table 1.

Patient’s characteristics.

Features
Age at initial diagnosis in years
Median (range)	5.0 (8 months–10 years)
Age at onset of blinatumomab
Median (range)	8.0 (1–17 years)
Sex (n (%))
Boys	8 (61.5%)
Girls	5 (38.5%)
Genetic aberration
ETV6-RUNX1	2
KMT2A	1
Hyperdiploidy	3
Hypodiploidy	1
No known genetic aberration	6
Disease status prior blinatumomab therapy
Refractory disease	1
1st relapse	10
2nd relapse	1
3rd relapse	1
Time of relapse
Very early (<18 months from diagnosis)	1
Early (>18 and <36 months from diagnosis)	2
Late (>36 months from diagnosis)	10
Leukemia load at onset of blinatumomab therapy (leukemic blasts in BM (%))
>50	1
25–50	2
5–25	0
<5	10
Extramedullary manifestation before onset of blinatumomab (n)
CNS * (facial nerves paralysis/infiltration in MRI)	1

BM—bone marrow; CNS—central nervous system. * Before onset of blinatumomab, patient presented resolution of leukemic infiltration in MRI image.